The 10-second takeaway
For the quarter ended June 30 (Q2), Impax Laboratories beat expectations on revenues and crushed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share improved significantly.
Gross margins contracted, operating margins increased, and et margins improved.
Impax Laboratories booked revenue of $166.5 million. The 11 analysts polled by S&P Capital IQ foresaw revenue of $160.9 million on the same basis. GAAP reported sales were 32% higher than the prior-year quarter's $125.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.60. The 11 earnings estimates compiled by S&P Capital IQ anticipated $0.44 per share. GAAP EPS of $0.27 for Q2 were 42% higher than the prior-year quarter's $0.19 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 46.8%, 60 basis points worse than the prior-year quarter. Operating margin was 21.0%, 490 basis points better than the prior-year quarter. Net margin was 11.2%, 120 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $161.5 million. On the bottom line, the average EPS estimate is $0.48.
Next year's average estimate for revenue is $635.8 million. The average EPS estimate is $2.04.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 171 members rating the stock outperform and 12 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 43 give Impax Laboratories a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Impax Laboratories is hold, with an average price target of $24.89.
- Add Impax Laboratories to My Watchlist.